AMBER LIPPA: Open Payments
NPI 1871920439 · ATTLEBORO, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,005 in 83 payments from 14 companies in 2025. Trend: 2023 $1,186 · 2024 $1,292 · 2025 $2,005
Food & beverage: $2,005
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $539 |
| QOL Medical, LLC | 8 | $306 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $169 |
| Ardelyx, Inc. | 15 | $165 |
| Janssen Biotech, Inc. | 9 | $153 |
| GENZYME CORPORATION | 4 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $129 |
| Madrigal Pharmaceuticals | 3 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $83 |
| Aimmune Therapeutics, Inc. | 3 | $57 |
Products named: Sucraid, DUPIXENT, CREON, XIFAXAN, IBSRELA, TREMFYA, ENTYVIO, RINVOQ.
Industry payments across MA — which companies pay providers there.
